633 results on '"Filleron, T."'
Search Results
52. 1401P Impact of KRAS mutation on non-small cell lung cancer survival outcomes
53. 1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
54. 923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
55. 557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
56. 110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France
57. 109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France
58. Traitements de première ligne et prise en charge du cancer broncho-pulmonaire non à petites cellules avancé ou métastatique avec une mutation EGFR–Analyse de la base nationale de données de vie réelle du programme Épidémio-stratégie médico-économique
59. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France
60. Carcinome micro-invasif du sein : caractéristiques clinico-pathologiques, traitement et pronostic
61. PO-1559: Survival prediction in GBM using radiomics of multimodal imaging
62. 128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
63. 250P Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database
64. Improving patient selection for immuno-oncology phase I trials: An external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O)
65. P1.01-120 Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy
66. PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial
67. Éditorial
68. Intérêt des modèles de guérison dans le cadre des essais d’immunothérapie
69. PO-0957 Radiomics study from the dose-painting multicenter phase III trial on newly diagnosed glioblastoma
70. Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database
71. Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort
72. Abstract GS1-08: Genomic characterisation of metastatic breast cancer
73. Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients
74. CHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists
75. Évaluation des critères cliniques, pathologiques et moléculaires prédictifs de réponse à l’immunothérapie anti-PD1 dans le mélanome métastatique : analyse rétrospective de 70 patients
76. Prise en charge des patients atteints d’un cancer bronchopulmonaire à petites cellules de stade IV – Analyse de la base nationale de données de vie réelle du programme Épidémio-Stratégie Médico-Économique (ESME)
77. Exploratory Dosimetric Study of the Impact of the Pre-Radiation Therapy Intra Tumoral Injection of Hafnium Oxide Nanoparticles Along the Radiation Treatment of Extremity and Trunk Wall Soft Tissue Sarcomas
78. VOTRAGE study pazopanib in a population of “frail” elderly patients after geriatric assessment: A phase I study with geriatric criteria
79. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
80. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas
81. The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients
82. Alternative methodological approach to randomized trial for surgical procedures routinely used
83. Comparaison de différentes méthodes de sélection de variables dans le cadre de données à haute dimension : application aux données de survie
84. Utilisation du score de propension : application aux données ESME, pour évaluer l’activité de l’Eribuline en pratique réelle chez les patients atteints d’un cancer du sein métastatique
85. Étude par simulation visant à évaluer l’influence de différents paramètres sur les résultats d’un essai randomisé d’algorithme dans le contexte de la médecine de précision
86. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
87. Abstract PD8-12: Mutational processes, genome evolution and outcome in metastatic breast cancers
88. Abstract P3-12-10: First 6-month report of the longitudinal PHACS study (Pharmacology and Hormonotherapy (HT) for Adjuvant breast Cancer (BC) Study, NCT01127295)
89. Abstract P2-02-05: Persistence of PIK3CA mutations detection in cell free tumor DNA as surrogate markers for hormonosensibility in patients with hormone receptor-positive breast cancer. The miRho clinical study
90. Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials
91. Total body irradiation using Helical Tomotherapy ® : Treatment technique, dosimetric results and initial clinical experience
92. Cell‐assisted lipotransfer: Friend or foe in fat grafting? Systematic review and meta‐analysis
93. L’évaluation précoce de la variation du ctDNA est un facteur prédictif de rechute des patients traités par immunothérapie
94. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
95. Planning posttherapeutic oncology surveillance visits based on individual risk
96. Successful Phase 2 Trial of Ultrafocal Brachytherapy for Low/Intermediate Risk Prostate Cancer
97. Calcul du nombre de sujets nécessaires dans les essais cliniques en oncologie avec un ou plusieurs critères de jugement de temps jusqu’à événement: package R coprimary
98. Comment prendre en compte l’hétérogénéité dans le schéma des essais cliniques de phase II en oncogériatrie ?
99. Abstract P6-09-05: Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab
100. Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.